進行性悪性腫瘍患者におけるLHC165単剤療法およびPDR001との併用療法の安全性と有効性に関する研究

基本情報

NCT ID: NCT03301896
ステータス: 中止
試験のフェーズ: 第1相
試験タイプ: 介入
目標被験者数: 45
治験依頼者名: Novartis

概要

The purpose of this trial was to explore the clinical utility of two investigational agents in patients with advanced cancer. This was a multi-center, open-label Phase I/Ib study. The primary objectives of the trial were: * To characterize the safety and tolerability of intratumoral LHC165 in patients with solid tumors as a single agent and in combination with PDR001 * To determine and evaluate the maximum tolerated dose (MTD)/recommended dose (RD) for LHC165 as a single agent and in combination with PDR001

対象疾患

Solid Tumors

介入

LHC165(DRUG)

PDR001(BIOLOGICAL)

依頼者（Sponsor）

ノバルティスファーマ株式会社(INDUSTRY)